In this non-partnered program, we developed CLR-TS for targeted delivery of antivirals (TargoVir™) to eradicate intracellular viral reservoirs in the form of infectious virions and/or proviral DNA integrated into the host cell’s genome.


While no treatments are currently available for clearing such reservoirs, our approach is intended to completely eradicate these pathogens; this may for the first time enable curative treatments for such chronic infections. In addition, because of the multimodal effect of the active compound RBT-05, this treatment may clear viral co-infections that further worsen the patients’ prognoses.

TargoVir™ is constructed with the CLR-TS, encapsulating the antiviral and virucidal compound RBT-05, a carbohydrate binding agent (CBA) that attaches to surface glycans on the viral envelope, allowing it to inactivate a broad range of viral pathogens. These include the hepatitis viruses HBV, HCV and HDV, the human immunodeficiency virus, type 1 (HIV-1), as well viruses with considerable epidemic risk potential such as the Ebola and Marburg viruses.

Back To Top